Shanton Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Shanton Screens First Subjects in Phase 2b Refractory/Tophaceous Gout Study with SAP-001

/PRNewswire/ Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and tophaceous gout patients, today.

Chen xuUnited statesBing liShanton pharmaPrnewswire shanton pharmaZhenhua huangNational healthNutrition examinationBusiness developmentContemporary prevalenceDecadal trendsNutrition examination surveyArthritis care res

Shanton Pharma: Shanton Screens First Subjects in Phase 2b Refractory/Tophaceous Gout Study with SAP-001

SAP-001 is an oral once-a-day investigational gout product with Best-in-Class potential for acute and chronic use in uncontrolled patients BRIDGEWATER, N.J., Jan. 9, 2023 /PRNewswire/

Chen xuUnited statesBing liShanton pharmaPrnewswire shanton pharmaZhenhua huangNational healthNutrition examinationBusiness developmentContemporary prevalenceDecadal trendsNutrition examination surveyArthritis care res

Shanton Screens First Subjects in Phase 2b Refractory Tophaceous Gout Study with SAP-001

- SAP-001 is an oral once-a-day investigational Gout product with Best-in-Class potential for acute and chronic use in uncontrolled patients BRIDGEWATER, .

Shanton pharmaShanton screens first subjectsTophaceous gout study

Overcoming Obstacles in the Management of Uncontrolled Gout: Rapid Response From Copenhagen

Overcoming Obstacles in the Management of Uncontrolled Gout: Rapid Response From Copenhagen
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesBoston universityFrance generalRonalda codarioN lawrence edwardsHopital lariboisiShanton pharmaTuhina neogiPascal richetteAlans cohenAccreditation council for continuing medical educationDrug administrationBoston university school of public healthEuropean alliance of associationsHorizon therapeutics united states incUniversity of florida college medicine

The Chronic Gout Market is Expected to Witness Remarkable Growth at a CAGR of 5 44% During the Study Period (2018-30), Assesses DelveInsight

/PRNewswire/ DelveInsight s Chronic Gout Market Insights report includes a comprehensive understanding of current treatment practices, Chronic Gout emerging.

United statesUnited kingdomShruti thakurLaboratorios sophiaVaxil biotherapeuticsLegochem biosciencesZydus cadilaTeijin pharmaJiatan pharmatechArthrosi therapueticsArchivel farmaPrnewswire delveinsightChong kun dangVera myelofibrosisShanton pharmaSelecta biosciences